Revascularization
Implementation of FFR-CT program at national level tied to improved outcomes at 2 years
Implementation of a CT angiography-derived fractional flow reserve program on a national level was associated with reduced risk for mortality and fewer downstream CV tests at 2 years, according to the results of the FISH&CHIPS study.
Transcatheter deep venous arterialization system for CLTI gains FDA approval
LimFlow announced that its transcatheter deep venous arterialization system for treatment of chronic limb-threatening ischemia was approved by the FDA.
FIRE: Complete revascularization benefits older patients with MI, multivessel disease
In patients aged 75 years or older with MI and multivessel CAD, physiology-guided complete revascularization improved outcomes compared with treating the culprit lesion only, according to the results of the FIRE trial.
Complete revascularization likely improves HF risk in those with ACS plus multivessel CAD
Complete revascularization was associated with reduced HF hospitalization and both CV and all-cause death among patients presenting with ACS and multivessel CAD, researchers reported in the Journal of the American Heart Association.
Large race disparities persist for Black, Hispanic adults with peripheral vascular disease
Compared with white patients, Black and Hispanic patients with peripheral vascular disease are younger, have more comorbidities, are less likely to undergo revascularization and more likely to undergo amputation, national data show.
Trial of vitamin D supplementation raises questions about CV effects on older adults
In a trial of more than 20,000 older adults, vitamin D supplementation trended toward reducing risk for major CV events in older adults compared with placebo, a finding differing from previous studies.
Ticagrelor monotherapy after PCI poses no extra revascularization risk vs. continued DAPT
Ticagrelor monotherapy after 3-month dual antiplatelet therapy was not associated with greater risk for repeat revascularization or MACCE at 1 year after PCI vs. continued DAPT, a speaker reported.
5-year data show titanium-nitride-oxide coated stents may be safer than DES
In patients with ACS, there were no differences in 5-year risk for cardiac death, MI or target lesion revascularization for those who received titanium-nitride-oxide-coated stents vs. biodegradable polymer drug-eluting stent, data show.
BIOVASC
Testing whether immediate complete revascularization is noninferior to staged (within 6 weeks after index procedure) complete revascularization in patients with ACS and multivessel CAD.
Immediate complete revascularization noninferior to staged in ACS, multivessel CAD
NEW ORLEANS — In patients with ACS and multivessel CAD who underwent PCI, immediate complete revascularization was noninferior to staged complete revascularization, according to results of the BIOVASC trial.